Naprelan®, which is patent protected, is currently the only once-a-day branded formulation of naproxen sodium. This formulation reduces GI side effects and significantly improves dosing compliance for patients suffering from pain.
Connected to the said acquisition, Victory has secured a manufacturing and supply agreement with Elan Pharma International Ltd (a subsidiary of Elan Corporation plc) – the developer of Naprelan®.
Elan will continue to manufacture Naprelan® at their GMP facility in Athlone, Ireland.
According to Mike Goolsby, Vice President of Sales, Victory Pharma:
"The sales of Naprelan have more than doubled since Victory started promoting the product through its dedicated sales force in January 2007. I have never experienced such a rapid rate of growth. The Naprelan® acquisition represents a significant milestone for Victory since it helps to secure our position in the large and unsatisfied non-steroidal anti-inflammatory market."Find more details from the full report (a pdf file).
Comment Preview